Pharmacological inhibition of intestinal FXR by Z-guggulsterone can ameliorate HFD-induced MASLD phenotypes, mirroring the metabolic improvements observed in intestine-specific FXR knockout mice (13). Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.